Tag: Avidity

FDA, Regulations

FDA gives orphan drug status to Avidity’s rare muscular dystrophy treatment

February 15, 2023


The candidate will now benefit from the incentives given to those drugs granted orphan status through the FDA’s ODD programme, introduced by the organisation to improve the availability of treatments for rare diseases. FSHD is characterised by the life-long, progressive […]